Эпизоды
-
Please visit answersincme.com/BRY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses current and emerging strategies to optimize the multidisciplinary care of advanced basal cell carcinoma (BCC) with immunotherapy.Upon completion of this activity, participants should be better able to: Identify patients with BCC for whom a second-line immunotherapy regimen would be appropriate; Review the clinical profiles of immunotherapy-based regimens for the second-line treatment of advanced BCC; and Outline multidisciplinary strategies to optimize the long-term care of patients with advanced BCC who are on an immunotherapeutic approach.
-
Please visit answersincme.com/FVG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical impact of novel and emerging tyrosine kinase 2 (TYK2) inhibitors in the treatment of patients with plaque psoriasis who are candidates for systemic therapy. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs for patients with plaque psoriasis who are candidates for systemic therapy; Describe the clinical impact of novel and emerging TYK2 inhibitors in the treatment of eligible patients with plaque psoriasis; and Outline strategies to optimize outcomes for patients with plaque psoriasis who may be candidates for systemic treatment with a TYK2 inhibitor.
-
Пропущенные эпизоды?
-
Please visit answersincme.com/QWR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evidence for and appropriate use of newly approved and emerging biologic therapies for the treatment of prurigo nodularis (PN). Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating biologic therapies to address unmet therapeutic needs for patients with PN; Describe the clinical profiles of approved and emerging biologic therapies for the treatment of PN; and Outline approaches to optimally integrate biologic therapies into treatment plans for PN.
-
Please visit answersincme.com/GDX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the clinical impact of approved and emerging combination treatments for advanced melanoma. Upon completion of this activity, participants should be better able to: Identify the unmet treatment needs for patients with advanced melanoma within the current therapeutic landscape; Recognize the mechanism of action of anti-lymphocyte activation gene-3 (anti-LAG-3) plus programmed cell death protein 1 (PD-1) combinations for the treatment of advanced melanoma; and Describe the clinical impact of approved and emerging anti-LAG-3 plus PD-1 combinations for the treatment of advanced melanoma.
-
Please visit answersincme.com/WZE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses strategies for optimizing immunotherapy in advanced basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Identify patients with advanced BCC who may benefit from immunotherapy; Review the clinical impact of available and emerging immunotherapies for the management of patients with advanced BCC; and Describe practical strategies to manage and monitor patients with advanced BCC on immunotherapy over both the long and short term.
-
Please visit answersincme.com/FDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical evidence for novel Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe the latest clinical evidence for novel JAK inhibitors in the treatment of moderate-to-severe AD; Outline practical strategies to manage adverse events associated with JAK inhibitors for the treatment of moderate-to-severe AD; and Identify patients with moderate-to-severe AD who might benefit from treatment with novel JAK inhibitors.
-
Please visit answersincme.com/GZT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the latest data in systemic treatments for children with moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Recognize the rationale for treatment intensification with novel systemic agents when managing children with moderate-to-severe atopic dermatitis (AD); Review the latest clinical data informing the current and future use of novel systemic agents in children with moderate-to-severe AD; and Identify opportunities for shared decision-making to improve the care of children with moderate-to-severe AD.
-
Please visit answersincme.com/ERJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts, one in oncology and another in dermatology, discuss strategies for diagnosis and management of hand-foot skin reaction. Upon completion of this activity, participants should be better able to: Recognize hand-foot skin reaction (HFSR) in patients being treated with multikinase inhibitors; Discuss the rationale for comprehensive management of HFSR in patients taking multikinase inhibitors; and Outline strategies for optimal HFSR management, including patient education to promote self-management.
-
Please visit answersincme.com/MTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in eosinophilic gastrointestinal disease discusses the diagnosis and underlying pathophysiology targeted by potential treatments for eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Describe the burden associated with delayed detection and inadequate treatment of EoE; Identify strategies to provide timely diagnosis of EoE; and Recognize the therapeutic rationale for targeting type 2 inflammation factors to treat EoE.
-
Please visit answersincme.com/KVB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the impact of emerging biologics on the treatment of moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for emerging biologic agents that target interleukin (IL)-13 cytokines for moderate-to-severe AD; and Outline how the latest data may inform the future use of emerging biologic agents that target IL-13 cytokines for moderate-to-severe AD within the context of the current treatment landscape.
-
Please visit answersincme.com/UVN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses advanced melanoma. Upon completion of this activity, participants should be better able to: Describe the clinical profiles for emerging LAG-3 inhibitors as treatment for selected patients with advanced melanoma; Identify patients with advanced melanoma who may benefit from LAG-3 inhibitors based on available evidence; and Explain strategies to monitor the use of LAG-3 inhibitors in patients with advanced melanoma to enhance patient outcomes.
-
Please visit answersincme.com/AYV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the therapeutic rationale for TYK2 inhibition, the clinical profiles of oral TYK2 inhibitors, and the potential impact these inhibitors may have on current treatment algorithms for moderate-to-severe psoriasis. Upon completion of this activity, participants should be better able to: Review how TYK2 inhibitors can differentially target the disease pathology of psoriasis compared to other JAK inhibitors; Compare the clinical profiles of novel TYK2 inhibitors and previously investigated JAK inhibitors for the treatment of moderate-to-severe psoriasis; and Identify strategies to optimally incorporate TYK2 inhibitors into practice, as they become available, for the management of patients with moderate-to-severe psoriasis.
-
Please visit answersincme.com/YSS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the use of Janus kinase inhibitors (JAKi) for the treatment of moderate-to-severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Review the updated treatment landscape for moderate-to-severe atopic AD, including the latest clinical data for novel JAKi; Outline strategies to manage adverse events associated with JAKi indicated for the treatment of moderate-to-severe AD; and Identify patients with AD who might benefit from treatment with novel JAKi.
-
Please visit answersincme.com/CHA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer management discusses current and future treatment strategies to manage patients with advanced nonmelanoma skin cancer (NMSC), including cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Propose patient and disease-related factors that could help determine the optimal treatment strategies for patients suffering from advanced NMSC; Describe the efficacy and safety of immunotherapies in the management of the most common NMSCs, BCC and CSCC; Identify the potential place of immunotherapies in the treatment plan for patients with NMSC.
-
Please visit answersincme.com/RKA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric dermatology discusses identifying and treating moderate-to-severe atopic dermatitis (AD) using two patient cases. Upon completion of this activity, participants should be better able to: Identify patients who have moderate-to-severe AD and may benefit from intensified therapy; Outline the latest evidence for biologic therapies that may be used for the treatment of patients with moderate-to-severe AD now and into the future; and Apply practical approaches to optimize the management of patients with moderate-to-severe AD long-term.
-
Please visit answersincme.com/VSF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in atopic dermatitis (AD) discusses balancing treatment efficacy and safety along with patient perspectives to optimize the management of moderate-to-severe AD. Upon completion of this activity, participants should be better able to: Differentiate the efficacy and safety of biologic and small molecule systemic therapies used in the treatment of moderate-to-severe AD based on recent clinical evidence; Identify patient-, disease-, and drug-related factors that may be used to individualize the use of systemic treatments for moderate-to-severe AD; and Design individualized treatment plans incorporating the patient perspective to balance the efficacy and safety of moderate-to-severe AD treatment.
-
Please visit answersincme.com/QNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in immunology discusses shingles prevention strategies for patients with immune-mediated diseases. Upon completion of this activity, participants should be better able to: Recognize the risk factors and clinical burden of shingles; Evaluate the current recommendations and clinical evidence on shingles vaccination in patients with immune-mediated diseases; and Implement patient-centered, evidence-based strategies to improve shingles vaccine uptake and series completion.
-
Please visit answersincme.com/ZBK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatologic diseases discusses the latest evidence in treatment of children with moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Recognize the impact that moderate-to-severe atopic dermatitis (AD) has on children, and the rationale for systemic treatment to improve patient quality of life; Identify the most recent clinical data for the use of systemic therapies in children with moderate-to-severe AD; and Translate the latest evidence regarding systemic therapies into management strategies for children with moderate-to-severe AD, now and in the future.
